

**Disclosure Purpose:** 21-16185

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-16185

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Efficacy and Safety of NVX-CoV2373 in Adults in the U.S. and Mexico
- 3. **Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16185

Summary of Interests

| Company or Organization   |              |   |
|---|--------------|---|
| Entity  | Type         | Interest Held By  |
| Novavax, Inc.   | Employment   | Self  |
| <i>Title:</i> Senior Director<br><i>Additional Information:</i> |              | <i>Position Description:</i> Clinical Development physician |
| Novavax, Inc.   | Stock        | Self  |
| <i>Additional Information:</i>                                  |              |   |
| Novavax, Inc.   | Stock Option | Self  |
| <i>Additional Information:</i>                                  |              |   |

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico
- Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-16185

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of NVX-CoV2373 in Adults in the U.S. and Mexico
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16185

Summary of Interests

**Company or Organization**

| Entity  | Type         | Interest Held By   |
|---|--------------|--|
| NVAX  | Employment   | Self   |
| <i>Title:</i> Vice President, Biostatistics<br><i>Additional Information:</i> |              | <i>Position Description:</i> Head of Biostatistics Group |
| NVAX  | Stock Option | Self   |
| <i>Additional Information:</i>  |              |  |

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Safety and Efficacy of the NVX-CoV2373 Covid-19 Vaccine
- Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-16185

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Efficacy and Safety of NVS-CoV2373 in Adults in the U.S. and Mexico
- 3. **Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-16185

## Summary of Interests

| Company or Organization  |                  |   |
|--|------------------|---|
| Entity   | Type             | Interest Held By  |
| National Institutes of Health  | Grant / Contract | Self  |
| <i>Recipient Name:</i> Lawrence Corey<br><i>Grant / Contract Description:</i> UM1 AI068614<br><i>Additional Information:</i> |                  | <i>Recipient Type:</i> Institution<br><i>Grant / Contract Purpose:</i> Research |

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of NVX-CoV2373 in Adults in the U.S. and Mexico
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-16185

## Summary of Interests

| Company or Organization  |            |   |
|--|------------|---|
| Entity   | Type       | Interest Held By                                      |
| Novavax  | Employment | Self  |
| <i>Title:</i> Chief Medical Officer<br><i>Additional Information:</i> I am a full-time employee and own stock in Novavax |            | <i>Position Description:</i> Executive Vice-President |

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-16185

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Efficacy and Safety of NVX-CoV2373 in Adults in the U.S. and Mexico
- 3. **Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16185

Summary of Interests

**Company or Organization**

| Entity   | Type       | Interest Held By                                 |
|--|------------|--|
| Novavax, Inc   | Employment | Self   |
| <i>Title:</i> Vice President, Clinical Development<br><i>Additional Information:</i> |            | <i>Position Description:</i> Global Medical Lead |

Additional Questions:

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico

3. Are you the corresponding author?

Yes.

a. Please list the other authors' names here.

Karen L. Kotloff, M.D.\*, Cynthia L. Gay, M.D., M.P.H.\*, Germán Áñez, M.D., Jeffrey M. Adelglass, M.D., Alejandro Q. Barrat Hernández, M.D., Wayne L. Harper, M.D., Daniel M. Duncanson, M.D., Monica A. McArthur, M.D., Ph.D., Jeffrey A. Jacqmein, M.D., Diana F. Florescu, M.D., R. Scott McClelland, M.D., M.P.H., Veronica Garcia-Fragoso, M.D., Robert A. Riesenber, M.D., David B. Musante, M.D., David L. Fried, M.D., Beth E. Safirstein, M.D., Mark McKenzie, M.D., Robert J. Jeanfreau, M.D., Jeffrey K. Kingsley, D.O., M.B.A., Jeffrey A. Henderson, M.D., M.P.H., Dakotah C. Lane, M.D., Guillermo M. Ruiz-Palacios, M.D., Lawrence Corey, M.D., Kathleen M. Neuzil, M.D., M.P.H., Robert W. Coombs, M.D., Ph.D., Alex L. Greninger, M.D., Ph.D., M.S., M.Phil., Julia Hutter, M.D., Julie A. Ake, M.D., M.Sc., Katherine Smith, M.D., Wayne Woo, M.S., Iksung Cho, M.S., Gregory M. Glenn, M.D., and Filip Dubovsky, M.D., M.P.H. for the 2019nCoV-301 Study Group\*\*

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16185

## Summary of Interests

### Company or Organization

| Entity  | Type                       | Interest Held By  |
|---|----------------------------|---|
| <a href="#">Astellas Pharma</a>   | Grant / Contract           | Other - University  |
| <i>Recipient Name:</i> UNMC<br><i>Grant / Contract Description:</i><br><i>Additional Information:</i> |                            | <i>Recipient Type:</i> Institution<br><i>Grant / Contract Purpose:</i> Research |
| <a href="#">Medpace</a>   | Data And Safety Monitoring | Self  |
| <i>Category:</i> Data And Safety Monitoring<br><i>Additional Information:</i>                         |                            | <i>Description:</i>   |
| <a href="#">Merck</a>   | Grant / Contract           | Other - UNMC  |
| <i>Recipient Name:</i> UNMC<br><i>Grant / Contract Description:</i><br><i>Additional Information:</i> |                            | <i>Recipient Type:</i> Institution<br><i>Grant / Contract Purpose:</i> Research |
| <a href="#">Merck</a>   | Consultant                 | Self  |
| <i>Category:</i> Consultant<br><i>Additional Information:</i>   |                            | <i>Description:</i>   |
| <a href="#">NobelPharma</a>   | Grant / Contract           | Other - UNMC  |
| <i>Recipient Name:</i> UNMC<br><i>Grant / Contract Description:</i><br><i>Additional Information:</i> |                            | <i>Recipient Type:</i> Institution<br><i>Grant / Contract Purpose:</i> Research |
| <a href="#">Novavax</a>   | Grant / Contract           | Other - UNMC  |
| <i>Recipient Name:</i> UNMC<br><i>Grant / Contract Description:</i><br><i>Additional Information:</i> |                            | <i>Recipient Type:</i> Institution<br><i>Grant / Contract Purpose:</i> Research |
| <a href="#">Regeneron Pharmaceuticals</a>   | Grant / Contract           | Other - UNMC  |
| <i>Recipient Name:</i> UNMC<br><i>Grant / Contract Description:</i><br><i>Additional Information:</i> |                            | <i>Recipient Type:</i> Institution<br><i>Grant / Contract Purpose:</i> Research |
| <a href="#">Takeda Oncology</a>   | Grant / Contract           | Other - UNMC  |
| <i>Recipient Name:</i> UNMC<br><i>Grant / Contract Description:</i><br><i>Additional Information:</i> |                            | <i>Recipient Type:</i> Institution<br><i>Grant / Contract Purpose:</i> Research |
| <a href="#">Takeda Oncology</a>   | Consultant                 | Self  |
| <i>Category:</i> Consultant<br><i>Additional Information:</i>   |                            | <i>Description:</i>   |

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?  
No.
- What is the manuscript title?  
Efficacy and Safety of NVX-CoV2373 in Adults in the U.S. and Mexico
- Are you the corresponding author?  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-16185

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

Yes.

a. **Please describe those relationships.**

I'm unsure if this applies, but I was PI for a high enrolling site for this study.

2. **What is the manuscript title?**

Efficacy and Safety of an Adjuvanted SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (NVX-CoV2373) in the United States and Mexico

3. **Are you the corresponding author?**

No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-16185

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico
- 3. **Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16185

Summary of Interests

**Company or Organization**

| Entity  | Type  | Interest Held By  |
|---|-------|---|
| novavax   | Other | Self  |
| <i>Category:</i> Other  |       | <i>Description:</i> Co-Chair on the trial reported in submitted manuscript but did not receive funding from the co. |
| <i>Additional Information:</i> As above, I did not receive funding from the company as trial was funded by the US government. |       |   |

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of NVX-CoV2373 in Adults in the U.S. and Mexico,
- Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-16185

## Summary of Interests

| Company or Organization   |            |                              |
|---|------------|------------------------------|
| Entity  | Type       | Interest Held By             |
| Novavax, Inc  | Employment | Self                         |
| <i>Title:</i> President, Research & Development<br><i>Additional Information:</i> |            | <i>Position Description:</i> |
| Novavax, Inc  | Stock      | Self                         |
| <i>Additional Information:</i> Stakeholder  |            |                              |

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Safety and Efficacy of the NVX-CoV2373 Covid-19 Vaccine
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16185

## Summary of Interests

| Company or Organization | Entity   | Type             | Interest Held By  |
|-------------------------|--|------------------|---|
|                         | <b>Abbott Molecular</b>  | Grant / Contract | Self  |
|                         | <i>Recipient Name:</i> University of Washington<br><i>Grant / Contract Description:</i> central testing<br><i>Additional Information:</i>        |                  | <i>Recipient Type:</i> Institution<br><i>Grant / Contract Purpose:</i> Research |
|                         | <b>Gilead Sciences</b>   | Grant / Contract | Self  |
|                         | <i>Recipient Name:</i> University of Washington<br><i>Grant / Contract Description:</i> sequencing HSV strains<br><i>Additional Information:</i> |                  | <i>Recipient Type:</i> Institution<br><i>Grant / Contract Purpose:</i> Research |
|                         | <b>Janssen Pharmaceuticals</b>   | Grant / Contract | Self  |
|                         | <i>Recipient Name:</i> University of Washington<br><i>Grant / Contract Description:</i> central testing<br><i>Additional Information:</i>        |                  | <i>Recipient Type:</i> Institution<br><i>Grant / Contract Purpose:</i> Research |
|                         | <b>LabCorp</b>   | Employment       | Spouse/Partner  |
|                         | <i>Title:</i> Employment<br><i>Additional Information:</i> salary  |                  | <i>Position Description:</i> microbiology director                              |
|                         | <b>Merck</b>   | Grant / Contract | Self  |
|                         | <i>Recipient Name:</i> University of Washington<br><i>Grant / Contract Description:</i> research<br><i>Additional Information:</i>               |                  | <i>Recipient Type:</i> Institution<br><i>Grant / Contract Purpose:</i> Research |
|                         | <b>Novavax</b>   | Grant / Contract | Self  |
|                         | <i>Recipient Name:</i> University of Washington<br><i>Grant / Contract Description:</i> central testing<br><i>Additional Information:</i>        |                  | <i>Recipient Type:</i> Institution<br><i>Grant / Contract Purpose:</i> Research |

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of NVX-CoV2373 in Adults in the U.S. and Mexico
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-16185

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
New England Journal of Medicine- 21-16185
- 3. **Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-16185

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-16185

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico
- 3. **Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-16185

## Summary of Interests

| Company or Organization                                       |            |  |
|---|------------|--|
| Entity  | Type       | Interest Held By                                       |
| ICON plc  | Other      | Self   |
| <i>Category:</i> Other<br><i>Additional Information:</i>      |            | <i>Description:</i> As PI, I conducted the trial.      |
| NOVAVAX   | Consultant | Self   |
| <i>Category:</i> Consultant<br><i>Additional Information:</i> |            | <i>Description:</i> I served on an advisory committee. |

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16185

Summary of Interests

**Company or Organization**

| Entity   | Type  | Interest Held By                           |
|--|-------|--|
| <a href="#">Merck</a>                                    | Other | Self                                       |
| <i>Category: Other</i><br><i>Additional Information:</i> |       | <i>Description: principal investigator</i> |
| <a href="#">NIAID</a>                                    | Other | Self                                       |
| <i>Category: Other</i><br><i>Additional Information:</i> |       | <i>Description: principal investigator</i> |
| <a href="#">novavax</a>                                  | Other | Self                                       |
| <i>Category: Other</i><br><i>Additional Information:</i> |       | <i>Description: principal investigator</i> |
| <a href="#">Regeneron Pharmaceuticals</a>                | Other | Self                                       |
| <i>Category: Other</i><br><i>Additional Information:</i> |       | <i>Description: principal investigator</i> |

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of NVX-CoV2373 in Adults in the U.S. and Mexico
- Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16185

Summary of Interests

**Company or Organization**

| Entity   | Type             | Interest Held By  |
|--|------------------|---|
| National Institutes of Health  | Grant / Contract | Self  |
| <i>Recipient Name:</i> Karen Kotloff<br><i>Grant / Contract Description:</i> Vaccine Treatment and Evaluation Unit<br><i>Additional Information:</i> Salary support in a grant to my institution |                  | <i>Recipient Type:</i> Institution<br><i>Grant / Contract Purpose:</i> Research |

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?  
No.
- What is the manuscript title?  
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico
- Are you the corresponding author?  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-16185

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-16185

## Summary of Interests

| Entity   | Type             | Interest Held By  |
|--|------------------|---|
| <a href="#">Moderna</a>  | Grant / Contract | Self  |
| <i>Recipient Name:</i> University of Maryland School of Medicine<br><i>Grant / Contract Description:</i> Co-investigator on a clinical trial<br><i>Additional Information:</i> I am a Co-investigator on a clinical trial investigating a COVID-19 vaccine candidate |                  | <i>Recipient Type:</i> Institution<br><i>Grant / Contract Purpose:</i> Research |
| <a href="#">Pfizer</a>   | Grant / Contract | Self  |
| <i>Recipient Name:</i> University of Maryland School of Medicine<br><i>Grant / Contract Description:</i> Co-investigator of a clinical trial<br><i>Additional Information:</i> I am a Co-investigator on a clinical trial investigating a COVID-19 vaccine candidate |                  | <i>Recipient Type:</i> Institution<br><i>Grant / Contract Purpose:</i> Research |

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
"Efficacy and Safety of an Adjuvanted SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (NVX-CoV2373) in the United States and Mexico"
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-16185

## Summary of Interests

| Company or Organization  |                  |   |
|--|------------------|---|
| Entity   | Type             | Interest Held By  |
| <a href="#">Gen-Probe, Inc.</a>  | Grant / Contract | Self  |
| <i>Recipient Name:</i> University of Washington<br><i>Grant / Contract Description:</i> Support for M. genitalium testing<br><i>Additional Information:</i> Funds paid to the University of Washington and donated testing supplies. |                  | <i>Recipient Type:</i> Institution<br><i>Grant / Contract Purpose:</i> Research |
| <a href="#">Lupin Pharmaceuticals, Inc</a>   | Consultant       | Self  |
| <i>Category:</i> Consultant<br><i>Additional Information:</i> One time consulting  |                  | <i>Description:</i> Consulting on BV treatment                                  |

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of NVX-CoV2373 in Adults in the U.S. and Mexico
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-16185

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico
- 3. **Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-16185

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Efficacy and Safety of NVX-CoV2373 in Adults in the U.S. and Mexico
- 3. **Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-16185

## Summary of Interests

| Company or Organization  |                  |  |
|--|------------------|--|
| Entity   | Type             | Interest Held By   |
| <a href="#">Pfizer</a>   | Grant / Contract | Self   |
| <i>Recipient Name:</i> Kathleen Neuzil<br><i>Grant / Contract Description:</i> Phase I Clinical trial of mRNA vaccine candidate<br><i>Additional Information:</i> Dr. Neuzil received no salary support. Her institution received support for conduct of this trial. |                  | <i>Recipient Type:</i> Individual<br><i>Grant / Contract Purpose:</i> Research |

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of NVX-CoV2373 in Adults in the U.S. and Mexico
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-16185

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of an Adjuvanted SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (NVX-CoV2373) in the United States and Mexico
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-16185

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and safety of NVC-CoV2373 in adults in the United States and Mexico
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-16185

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico
- 3. **Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.





**Disclosure Purpose:** 21-16185

## Summary of Interests

| Company or Organization   |            |                              |
|---|------------|------------------------------|
| Entity  | Type       | Interest Held By             |
| <a href="#">Novavax Inc</a>   | Employment | Self                         |
| <i>Title:</i> Vice President, Head Medical Safety<br><i>Additional Information:</i> |            | <i>Position Description:</i> |

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of NVX-CoV2373 in Adults in the US and Mexico
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16185

Summary of Interests

**Company or Organization**

| Entity   | Type       | Interest Held By                             |
|--|------------|--|
| Novavax  | Employment | Self   |
| <i>Title:</i> Senior Manager Biostatistics<br><i>Additional Information:</i> |            | <i>Position Description:</i> Biostatistician |
| Novavax  | Stock      | Self   |
| <i>Additional Information:</i> Unvested grant of company stock               |            |  |

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of NVX-CoV2373 in Adults in the U.S. and Mexico
- Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

